景嘉微(300474.SZ):副總裁胡亞華擬將不超0.7967%股份平移至私募基金產品
格隆匯3月10日丨景嘉微(300474.SZ)公佈,公司於2022年3月10日收到副總裁胡亞華通知,因家庭資產規劃需要,胡亞華擬以大宗交易方式轉讓不超過公司總股本的0.7967%(即不超過240萬股)至私募基金產品(橫琴廣金美好基金管理有限公司—廣金美好啟航二號私募證券投資基金、廣金美好啟航三號私募證券投資基金,上海恆基浦業資產管理有限公司—恆基祥榮2號私募證券投資基金,合稱“一致行動人”)。
胡亞華已與一致行動人簽署了一致行動協議,該次股份變動系一致行動人之間內部進行的轉讓,不涉及向市場減持,不會導致股東及一致行動人合計持股比例和數量發生變化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.